PO-0716: High dose chemoradiation in glioblastoma patients: feasibility and safety of a phase I trial

• DOI: 10.1016/s0167-8140(18)31026-0
• Publication Date: 2018-06-18T18:17:07Z
• Authors: M. Ferro; G. Macchia; S. Cilla; A. Ianiro; S. Cammelli; V. Picardi; G. Giglio; M. Specchia; G.P. Frezza; G. Siepe; A. Arcelli; R. Frakulli; S. Ciabatti; S. Chiesa; M. Balducci; V. Valentini; A.G. Morganti; F. Deodato
• Keywords: 03 medical and health sciences; 0302 clinical medicine

ESTRO 37 S366 organ involved mean survival was only 1,347 months (σ=0,53) and median 0,6 (σ=0,25).All but one patient in this group died the next three after begin of radiotherapy.The patient, from who survived more than 6 month had a relapse hormone positive breast cancer with malignant pleura effusion drainage.In Cox regression analysis age adjusted hazard ratio for death 6,7 (p<0,001) compared patients normal markers without extracranial involvement.The difference overall between two best groups EC-S however not significant (p=0,78).In multivariate including DS-GPA each class showed correlation contrary to EC-S.Parameter n % Female 243 46,2 Male 283 53,8 Median age, years (range) 63,6 (20-92) Primary Lung 270 51,3